AFFLUENCE

On Standalone basis, the Company achieved gross revenue of Rs. 25,133.24 million as compared to Rs. 25,445.79 million in the previous year and the Standalone operating profit before Interest, Taxation, Depreciation, and Amortization was Rs. 5,610.36 million as compared to Rs. 6,612.84 million in the previous year.   On Consolidated basis, the Company achieved a gross revenue of Rs. 51,308.60 million as compared to Rs. 48,123.18 million in the previous year and the consolidated operating profit before Interest, Taxation, Depreciation and Amortization was Rs. 7,862.45 as compared to Rs. 8,439.10 million in the previous year.   

a)      Steps taken or impact on conservation of energy   Energy conservation continues to receive top priority in the Company. Energy audits are carried out, consumption monitored; maintenance systems improved and distribution losses are reduced.                         Specific Energy conservation measures undertaken by the Company are as follows:    1.      Use of Variable Frequency Drive (VFDs) in the existing air compressor system and also installation of dedicated Air Compressor at some plants. 2.      Switched over to LED light fixtures at most of the locations. 3.      Motion sensors are installed at main corridors for energy efficiency at some plants. 4.      Water is recycled, wherever possible. 5.      Use of EC motors in AHUs, wherever possible at Hinjawadi plant 6.      Automatic operation of cooling tower fan motor and installation of recirculation system for auto clave at Sanand Plant. 7.      Use of Briquette Boiler in place of HSD Boiler at Jammu plant. 8.      Air showers are activated by Motion Sensor and use of digital timers in place of convectional timers for fine control for street light at Kurkumbh plant.   b)     The steps taken by the company for utilising alternate sources of energy   Not applicable. c)      The capital investment on energy conservation equipment’s   Capital investment of Rs. 3.1 Mn was made on energy conservation equipment’s.

1.            Efforts, in brief, made towards technology absorption:   R&D as its core strength, has indulged into research of newer ways to deliver molecules for effective actions. In effort, new products and formulations for newer applications were developed through bio-availability and blood level studies at R & D activity.   R&D is working vigorously for development of novel drug delivery system like liposomal delivery, nanoparticles, lipid complex and micro-emulsion. Some of the products like liposomal delivery are advancing towards commercialization. Emcure has extended its arms in Transdermal Drug delivery system and achieved success. Moreover, we have broadened our research field and entered into depot injection (long acting microspheres). Novel research is ongoing in safety & efficacy enhancement for cytotoxic drug product.   The research team has developed and commercialized extended release dosage forms, multi particulate systems, pulsatile drug delivery system, osmotic drug delivery system etc.   2.            The benefits derived like product improvement, cost reduction, product development or import substitution:   Adopting improvements for betterment, Technology is been switched from Hot melt extrusion to Top spray granulation for molecules like Ritonavir or a Multi-layer FDC is been formulated into single layer formulation, a simplified version of complex technology.   Continued implementation of technology has yielded in product improvement and cost reduction, with respect to standardized analytical methods. Some of the benefits of these efforts reflected in better quality and stability of products. E.g. Extractable, leachable studies and characterisation studies of complex injectable generics have been established with in-house techniques to avoid dependence on outsourced parties as well as reduce the cost of development.   In API R&D several cost improvement (CIP) projects are initiated, e.g Dexketoprofen Trometamol, Propofol, Flecanide Acetate, Ropivacaine HCl, Acamprosate Calcium, Ritonavir etc. Imported intermediates and starting material were back-integrated with the help of in-house development of these intermediates and starting materials. This not only lowers the cost of these API but also make Emcure self-reliant for delivery of these APIs. All these were achieved without any major change to filed process thus ensuring availability and reliability of the above APIs for commercial supply.   3.      In case of imported technology (imported during the last three years reckoned from the beginning of the financial year):   No technology has been imported by the Company during the last 3 years.   4.      The expenditure incurred on Research and Development                        (Standalone)                                  (a)     Capital  Rs. 3.68 Million (FY 2019-20)  Rs. 17.26 Million (FY 2018-19) (b)     Revenue  Rs. 1,266.88 Million (FY 2019-20)  Rs. 1,630.22 Million (FY 2018-19) (c)      Total  Rs. 1,270.56 Million (FY 2019-20)  Rs. 1,647.48 Million (FY 2018-19) (d)     Total R & D Expenditure as % of gross turnover  5.35% (FY 2019-20)  6.71% (FY 2018-19)    

Foreign Exchange earned in terms of Actual Inflows 10,090.06 Millions Foreign Exchange outgo in terms of Actual Outflows 1,468.31 Millions      

Pursuant to the provisions of Sections 134(3)(c) and 134(5) of the Act, the Directors confirm that – I.        in the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures, if any; II.      appropriate accounting policies had been selected and applied them consistently and had made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs as at March 31, 2020 and of the profit of the Company for the year ended March 31, 2020; III.    proper and sufficient care had been taken for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities; IV.    the annual accounts had been prepared on a going concern basis; V.      they had laid down internal financial controls to be followed by the Company and such internal financial controls are adequate and were operating effectively; and VI. proper systems had been devised to ensure compliance with the provisions of all applicable laws and such systems were adequate and operating effectively.